Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment
Psychopharmacology, ISSN: 1432-2072, Vol: 81, Issue: 2, Page: 100-106
1983
- 46Citations
- 29Captures
- 4Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations46
- Citation Indexes44
- 44
- CrossRef40
- Policy Citations2
- Policy Citation2
- Captures29
- Readers29
- 29
- Mentions4
- References2
- Wikipedia2
- Blog Mentions1
- Blog1
- News Mentions1
- News1
Most Recent News
The Ultimate Guide To Piracetam: Benefits, Dosage, & More
Piracetam is one of the most popular nootropic drugs. It is also one of the oldest. Piracetam holds the distinction of being the first-ever supplement
Article Description
In a 12-week double-blind study, piracetam at two dose levels (2.4 and 4.8g/day) was compared to placebo in the treatment of 60 elderly psychiatric patients with mild diffuse cerebral impairment, but no signs of focal brain lesion. The psychiatric illness, schizophrenia or affective disorder, of patients selected was in remission at the time of the study. Monthly evaluations by the nurse revealed that piracetam improved overall functioning, particularly alertness, socialization, and cooperation, relative to the control group. Patients treated with 2.4g/day piracetam also showed significant improvement in scores for the full IQ and the memory quotient on the Wechsler Adult Intelligence and Memory Scales; greater response was seen in those with lower initial scores. Piracetam at 4.8g/day had a more rapid onset of action on behavioral variables than 2.4g/day, but its therapeutic effect tended to diminish at 12 weeks, possibly as the result of overstimulation. Piracetam did not appear to interfere with concomitant psychotropic maintenance medication or affect the psychiatric illness itself. © 1983 Springer-Verlag.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0020514842&origin=inward; http://dx.doi.org/10.1007/bf00429000; http://www.ncbi.nlm.nih.gov/pubmed/6415738; http://link.springer.com/10.1007/BF00429000; https://dx.doi.org/10.1007/bf00429000; https://link.springer.com/article/10.1007/BF00429000; http://www.springerlink.com/index/10.1007/BF00429000; http://www.springerlink.com/index/pdf/10.1007/BF00429000
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know